Community Bank N.A. Cuts Stock Position in Kenvue Inc. $KVUE

Community Bank N.A. lowered its position in Kenvue Inc. (NYSE:KVUE) by 1.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 72,181 shares of the company’s stock after selling 1,372 shares during the period. Community Bank N.A.’s holdings in Kenvue were worth $1,511,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of KVUE. Pittenger & Anderson Inc. acquired a new stake in Kenvue in the 1st quarter worth approximately $30,000. Trust Co. of Vermont boosted its stake in Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after purchasing an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC acquired a new stake in Kenvue in the 1st quarter worth approximately $36,000. Truvestments Capital LLC acquired a new stake in Kenvue in the 1st quarter worth approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its stake in Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $16.21 on Tuesday. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $15.47 and a 12 month high of $25.17. The company has a 50 day simple moving average of $19.03 and a two-hundred day simple moving average of $21.25. The stock has a market cap of $31.10 billion, a price-to-earnings ratio of 21.90, a PEG ratio of 2.39 and a beta of 0.72.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. During the same period in the previous year, the business posted $0.32 EPS. The business’s revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a dividend yield of 5.1%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Evercore ISI lowered their target price on shares of Kenvue from $23.00 to $18.00 and set an “in-line” rating for the company in a research note on Tuesday, September 23rd. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Canaccord Genuity Group lowered their target price on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $21.18.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.